Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Thanks guys. Would like to see VOX get Paul Jourdan on again, he was one of their regulars
Sharp move up in Saietta (SED) sp this morning after long decline.......the relevance here ? .....Saietta is(was ?) one of the larger holdings in Amati's VCT fund; but checking this morning it does not seem to be in top 10 holdings any more; also, Polarean now (as of 28th Feb) represents 3.3% of the fund and I'm pretty sure that this has come down from 5% a few months back. No change in %age holding on Polarean website by Amati but that may not be an up to date figure.
yes @jay, and i see that companies researching new drugs to treat, for example, asthma, will benefit greatly from this tech.....here is a picture of lung function before taking drug....here is a picture of lung function after taking drug. The market for research applications is obviously much smaller than for disease treatment. That is my question for POLX (that they haven't answered yet) : How does this tech help decide drug and treatment process in pulmonary hospitals and how does it save them money ?
That's my thoughts at the moment, that the sales market is limited to research hospitals and companies producing new drugs for pulmonary disease. Bracco and Amati surely must see a bigger market potential than just for research, but I am struggling to see it
Kromek still trading tho' and seem to be generating orders ? if its KMK you mean ?......maybe thats what will happen here, getting just enough business to survive.
All seems too vague here; for instance, asthma is a massive global problem and hence a massive market; POLX tech gives best images of lung function but how do those images change treatment process and how do they improve outcomes ? The company has still not answered the questions from the presentation a month ago
The Oxford study, led by Prof Gleeson, using xenon MRI, has been going on since pre-covid. They may have adapted it to study covid lung damage but its not a new story.
As far as I'm aware, that Oxford study was set up using govt grant money, and for me that's the real problem here; until POLX can demonstrate that hospitals, MRI manufacturers or new drug co's actually want to buy this product then sp is not going up.
Sadly @Lincolnite, the market has no-where near a £250m valuation for this company. With envisaged sales of 12 systems in the next 2 years, why would it ?
no director buys.....no-ones buying.
I have a holding in ZNWD, a lithium miner, with no mine , sp at about 75% of 2021 levels. This week they raised £18M at a placing and the price was at a 25% premium to the sp level. It shows what can be possible, but it was only possible because they brought in a cornerstone investor and the institutions bought in to maintain their % holdings.
We don't Know what happened here directly after the December approval, but it looks like they wanted to raise and it was botched. Directors may well have planned to buy in again at a raise.......maybe not.
My opinion is POLX need to demonstrate that there is demand for the product. Bracco, GE Healthcare, Amati, other MRI manufacturers know more than me how 'useful' and needed this product is; if one or more are not willing to invest in it at this point or to enter into some kind of JV then future does not look good.
About time POLX answered the questions that were submitted at the presentation, poor show again.
I think there is still downside here. Buyer beware !
Ah, OK @GracieP, your link shows they topped up their shares then, although their %age fell. Bracco topped up a bit more. I never was able to find out what happened to the AMP shares, as they were quite substantial holders. AMP went bust so whoever the creditor(s) were must have taken them over.
Amati could end up becoming a problem here, I haven't looked at the holdings in detail, but I know Saietta is one of their bigger positons and thats being battered as well. Hopefully they are managing their portfolio a bit better than I'm managing mine !
They bought in with the IPO ? was it 12p ? and I don't think they've added at placing. It does make you wonder why they didn't sell any shares coming up to the first FDA decision when they would have been in profit to the tune of 8X. Would have to be pre-arranged trade I expect but must be possible. Why not de-risk at that point?
If Amati do decide to sell now @ Lincolnite this is going to IPO levels; and to be honest, nearly 3 months since approval, if POLX don't make some sales a bt sharpish, its going there anyway
we track tin price but the sharp drop from 5p to here I assume has more to do with expansion funding . The orion financing has been dragging on for a long time and I still don't think is finalised. The banking problems at the moment will (have been perceived) not to have helped conclude any deal. Maybe some investors have been spooked and sold because of this ?
I feel your pain @Doppo, my average is about the same. I could average down some more but TBH I feel like I'm in a hole and the sensible thing is to stop digging. Could go down further without news/ director buying/institution buying. Think we're gonna be underwater for a long time yet.
Atlantic down 40% and suspended pending announcement ! I wouldn't have looked at it without your mention @oogle. TBH they were one of the 'safer' lithium stocks on AIM because of the piedmont interest. We are still tied to Sn price here but if we stay on track that should change
large trade at the end looks like a buy, but price action at close suggests otherwise. I don't think theres much upside here until we get sales news come through. As low as we are, I feel 65M mcap has some degree of sales and demand for product priced in . I'm still hoping we are on the radar of a bigger fish
Thank you SLF72......Seemed strange to me that POLX didn't update this information in recent investor presentation....and how the anticipated sales revenue would impact cash runway into 2024
I don't think the market has been too excited about POLX for a while now @ PYUECK, a lot of PIs took the approval as a get out point rather than a get in. Well done them.
Its difficult to put a value on the company right now. $500k for a system, $50k for a cylinder, but i still don't know how much profit they make on those sales. Over 24 mths they envisage the sale of 15 - 20 systems and 75-100 cylinders; that suggests they are not seeing strong demand for the product. I don't think we have sales news here until 2nd quarter and so i dont see trend reversal until that time.
I'm sitting on an average of about 58p so will have to look at bringing that down and try to catch this knife near the bottom. Institutions seem patient but the lack of buying is a worry. A take over bid below my price average ? not impossible
will not trump lithium for use in transportable applications ev's, phones, tools etc but because of lower cost could be a better option for fixed, not weight dependent, grid/power storage. Maybe a bigger competitor to the 'parent' company here......bushveld
off book trade arranged between a buyer and seller ? hence no sp reaction. If that amount gets put on the sell or ask, sp has to react, surely. Saying that, its not unusual for this stock to have big trades going through with no sp reaction
I wonder what the market was expecting that it has reacted so badly?
All Polarean have done really is just expand upon the last company update RNS . I can't really see that they've added any bad news that the market didn't already know.
Even after going thru the commercialisation bit I'm still none the wiser on expected revenue for next 24 mths: If they sell 75 cylinders and 15 systems then in theory that should generate circa $10M..... but how much will it cost to make and deliver said products ?
Maybe thats why market has dropped the price so much......p@@@ed off cos they haven't told us anything.
If anyone has asked these questions about production costs, and the company answers, please post them here.
I'm assuming that if they do have net revenue, they would be able to extend the May '24 date ?
a planned raise on the back of approval, hatch waxman AND a rising sp would have made sense; maybe because the sp tanked the company shelved it....hopefully find out Monday but I doubt they'll be very transparent.
The envisioned sales of gas and kit over 24mths sounds a bit underwhelming and possibly they have under promised and hoping to over deliver. There needs to be some sense of demand from a wider market otherwise the company will never turn a profit.
I think it would be better to tie up (or takeover) with one of the bigger players, they may not want to, but in current market could be the best move
would be nice now. They bought in after the CRL to show the faith, and at prices a fair bit higher. Shows how much market sentiment has changed over last 18mths. Could do with another interview with Proactive to flesh out that RNS a little bit.
Was looking a little better thru the afternoon today but the late reported might kibosh that
blimey!.......market guys having fun with this no news uncertainty